Information  X 
Enter a valid email address

Lifeline Scientific (LSI)

  Print      Mail a friend

Wednesday 24 June, 2009

Lifeline Scientific

Result of AGM

RNS Number : 3947U
Lifeline Scientific, Inc
24 June 2009
 



24 June 2009



Lifeline Scientific, Inc

Result of Annual General Meeting ('AGM')


Lifeline Scientific, the medical technology company focused on commercialising its LifePort® Kidney Transporter, held its Annual General Meeting yesterday at 4pm GMT, and Mr. David Kravitz and Dr. Steven Mayer were re-elected as Class II directors of the Company's Board of Directors. 


Enquiries

Lifeline Scientific, Inc.


David Kravitz, CEO


Seymour Pierce (Nomad)

+44 (0)20 7107 8000

Mark Percy / Huaizheng Peng / Sarah Jacobs            


Financial Dynamics

+44 (0)20 7831 3113

Ben Brewerton / John Dineen

 


About Lifeline Scientific Inc.  

Lifeline Scientific, Inc. is a Chicago-based global medical technology company with European headquarters located in Brussels. Its primary focus is to commercialise its FDA approved, CE marked, clinically validated and revenue generating LifePort Kidney Transporter. Devices for preservation of the heart, lung pancreas and liver are in late stage pre-clinical development. 


About the LifePort Kidney Transporter

Created with the challenges of organ recovery and transport in mind, LifePort Kidney Transporter is designed to provide improved kidney preservation, evaluation and transport prior to transplantation. LifePort provides a sealed, sterile, protected environment where a solution is gently pumped through the kidney at cold temperatures to minimize damage while the organ is outside the body. LifePort is lightweight and portable, allowing organs to be perfused from the time of recovery until transplant. It is designed to travel unaccompanied by land or air, safely transporting the kidneys across town or between countries. While the kidney is being perfused, the LifePort records data on temperature, flow rate vascular resistance and pressure every 10 seconds providing surgeons with additional data prior to transplant. During its pilot introduction, over 300 LifePorts have been installed in 90 transplant programmes worldwide treating more than 17,000 kidneys.  







This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGCKNKKDBKBQAB